Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Revisiting the case for genetically engineered mouse models in human myelodysplastic syndrome research

Ting Zhou, Marsha C. Kinney, Linda M. Scott, Sandra S. Zinkel, Vivienne I. Rebel

Blood (2015) 126 (9): 1057–1068.

https://doi.org/10.1182/blood-2015-01-624239

Published: 2015

Journal Articles

JAK2 V617F impairs hematopoietic stem cell function in a conditional knock-in mouse model of JAK2 V617F–positive essential thrombocythemia

Juan Li, Dominik Spensberger, Jong Sook Ahn, Shubha Anand, Philip A. Beer, Cedric Ghevaert, Edwin Chen, Ariel Forrai, Linda M. Scott, Rita Ferreira, Peter J. Campbell, Steve P. Watson, Pentao Liu, Wendy N. Erber, Brian J. P. Huntly, Katrin Ottersbach, Anthony R. Green

Blood (2010) 116 (9): 1528–1538.

https://doi.org/10.1182/blood-2009-12-259747

Published: 2010

Includes: Supplemental data

Journal Articles

The JAK2 46/1 haplotype predisposes to MPL -mutated myeloproliferative neoplasms

Amy V. Jones, Peter J. Campbell, Philip A. Beer, Susanne Schnittger, Alessandro M. Vannucchi, Katerina Zoi, Melanie J. Percy, Mary Frances McMullin, Linda M. Scott, William Tapper, Richard T. Silver, David Oscier, Claire N. Harrison, Harald Grallert, Aliaksei Kisialiou, Paul Strike, Andrew J. Chase, Anthony R. Green, Nicholas C. P. Cross

Blood (2010) 115 (22): 4517–4523.

https://doi.org/10.1182/blood-2009-08-236448

Published: 2010

Includes: Supplemental data

Journal Articles

MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort

Philip A. Beer, Peter J. Campbell, Linda M. Scott, Anthony J. Bench, Wendy N. Erber, David Bareford, Bridget S. Wilkins, John T. Reilly, Hans C. Hasselbalch, Richard Bowman, Keith Wheatley, Georgina Buck, Claire N. Harrison, Anthony R. Green

Blood (2008) 112 (1): 141–149.

https://doi.org/10.1182/blood-2008-01-131664

Published: 2008

Includes: Supplemental data

Journal Articles

Collaboration between Activating Mutations in JAK2 and Trisomy 21 in the Acute Lymphoblastic Leukemias of Down Syndrome (DS).

Blood (2007) 110 (11): LB6.

https://doi.org/10.1182/blood.V110.11.LB6.lb6

Published: 2007

Journal Articles

Demonstration of an aberrant mast-cell population with clonal markers in a subset of patients with “idiopathic” anaphylaxis

Cem Akin, Linda M. Scott, Can N. Kocabas, Nataliya Kushnir-Sukhov, Erica Brittain, Pierre Noel, Dean D. Metcalfe

Blood (2007) 110 (7): 2331–2333.

https://doi.org/10.1182/blood-2006-06-028100

Published: 2007

Journal Articles

Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations, and role in leukemic transformation

Peter J. Campbell, E. Joanna Baxter, Philip A. Beer, Linda M. Scott, Anthony J. Bench, Brian J. P. Huntly, Wendy N. Erber, Rajko Kusec, Thomas Stauffer Larsen, Stéphane Giraudier, Marie-Caroline Le Bousse-Kerdilès, Martin Griesshammer, John T. Reilly, Betty Y. Cheung, Claire N. Harrison, Anthony R. Green

Blood (2006) 108 (10): 3548–3555.

https://doi.org/10.1182/blood-2005-12-013748

Published: 2006

Journal Articles

Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrombocythemia

Linda M. Scott, Mike A. Scott, Peter J. Campbell, Anthony R. Green

Blood (2006) 108 (7): 2435–2437.

https://doi.org/10.1182/blood-2006-04-018259

Published: 2006

Includes: Supplemental data

Journal Articles

Lack of α4 integrin expression in stem cells restricts competitive function and self-renewal activity

Gregory V. Priestley, Linda M. Scott, Tatiana Ulyanova, Thalia Papayannopoulou

Blood (2006) 107 (7): 2959–2967.

https://doi.org/10.1182/blood-2005-07-2670

Published: 2006

Journal Articles

The V617F JAK2 Mutation Is Uncommon in Cancers and Mutations in STAT5A, STAT5B and the JAK Family Genes Do Not Account for V617F Negative Myeloproliferative Disorders.

Joanna E. Baxter, Linda M. Scott, Peter J. Campbell, Tony Todd, Philip Stephens, Sarah Edkins, Richard Wooster, Michael R. Stratton, Andrew P. Futreal, Anthony R. Green

Blood (2005) 106 (11): 2598.

https://doi.org/10.1182/blood.V106.11.2598.2598

Published: 2005

Journal Articles

The V617F JAK2 mutation is uncommon in cancers and in myeloid malignancies other than the classic myeloproliferative disorders

Linda M. Scott, Peter J. Campbell, E. Joanna Baxter, Tony Todd, Philip Stephens, Sarah Edkins, Richard Wooster, Michael R. Stratton, P. Andrew Futreal, Anthony R. Green

Blood (2005) 106 (8): 2920–2921.

https://doi.org/10.1182/blood-2005-05-2087

Published: 2005

Journal Articles

VCAM-1 expression in adult hematopoietic and nonhematopoietic cells is controlled by tissue-inductive signals and reflects their developmental origin

Tatiana Ulyanova, Linda M. Scott, Gregory V. Priestley, Yi Jiang, Betty Nakamoto, Pandelakis A. Koni, Thalia Papayannopoulou

Blood (2005) 106 (1): 86–94.

https://doi.org/10.1182/blood-2004-09-3417

Published: 2005

Includes: Supplemental data

Journal Articles

Absence αof 4 Integrin in Hemopoietic Stem Cells Limits Their Self-Renewal Potential in Vivo.

Thalia Papayannopoulou, Gregory V. Priestley, Linda M. Scott

Blood (2004) 104 (11): 118.

https://doi.org/10.1182/blood.V104.11.118.118

Published: 2004

Journal Articles

Molecular pathways in bone marrow homing: dominant role of α 4 β 1 over β 2 -integrins and selectins

Thalia Papayannopoulou, Gregory V. Priestley, Betty Nakamoto, Vivian Zafiropoulos, Linda M. Scott

Blood (2001) 98 (8): 2403–2411.

https://doi.org/10.1182/blood.V98.8.2403

Published: 2001

Journal Articles

Synergistic mobilization of hemopoietic progenitor cells using concurrent β1 and β2 integrin blockade or β2-deficient mice

Thalia Papayannopoulou, Gregory V. Priestley, Betty Nakamoto, Vivian Zafiropoulos, Linda M. Scott, John M. Harlan

Blood (2001) 97 (5): 1282–1288.

https://doi.org/10.1182/blood.V97.5.1282

Published: 2001

Journal Articles

Soluble stem cell factor receptor (CD117) and IL-2 receptor alpha chain (CD25) levels in the plasma of patients with mastocytosis: relationships to disease severity and bone marrow pathology

Cem Akin, Lawrence B. Schwartz, Takashi Kitoh, Hirokazu Obayashi, Alexandra S. Worobec, Linda M. Scott, Dean D. Metcalfe

Blood (2000) 96 (4): 1267–1273.

https://doi.org/10.1182/blood.V96.4.1267

Published: 2000

Journal Articles

Demonstration That Human Mast Cells Arise From a Progenitor Cell Population That Is CD34 + , c- kit + , and Expresses Aminopeptidase N (CD13)

Arnold S. Kirshenbaum, Julie P. Goff, Tekli Semere, Barbara Foster, Linda M. Scott, Dean D. Metcalfe

Blood (1999) 94 (7): 2333–2342.

https://doi.org/10.1182/blood.V94.7.2333.419k30_2333_2342

Published: 1999

NARROW

Revisiting the case for genetically engineered mouse models in human myelodysplastic syndrome research

JAK2 V617F impairs hematopoietic stem cell function in a conditional knock-in mouse model of JAK2 V617F–positive essential thrombocythemia

The JAK2 46/1 haplotype predisposes to MPL -mutated myeloproliferative neoplasms

MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort

Collaboration between Activating Mutations in JAK2 and Trisomy 21 in the Acute Lymphoblastic Leukemias of Down Syndrome (DS).

Demonstration of an aberrant mast-cell population with clonal markers in a subset of patients with “idiopathic” anaphylaxis

Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations, and role in leukemic transformation

Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrombocythemia

Lack of α4 integrin expression in stem cells restricts competitive function and self-renewal activity

The V617F JAK2 Mutation Is Uncommon in Cancers and Mutations in STAT5A, STAT5B and the JAK Family Genes Do Not Account for V617F Negative Myeloproliferative Disorders.

The V617F JAK2 mutation is uncommon in cancers and in myeloid malignancies other than the classic myeloproliferative disorders

VCAM-1 expression in adult hematopoietic and nonhematopoietic cells is controlled by tissue-inductive signals and reflects their developmental origin

Absence αof 4 Integrin in Hemopoietic Stem Cells Limits Their Self-Renewal Potential in Vivo.

Molecular pathways in bone marrow homing: dominant role of α 4 β 1 over β 2 -integrins and selectins

Synergistic mobilization of hemopoietic progenitor cells using concurrent β1 and β2 integrin blockade or β2-deficient mice

Soluble stem cell factor receptor (CD117) and IL-2 receptor alpha chain (CD25) levels in the plasma of patients with mastocytosis: relationships to disease severity and bone marrow pathology

Demonstration That Human Mast Cells Arise From a Progenitor Cell Population That Is CD34 + , c- kit + , and Expresses Aminopeptidase N (CD13)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only